17 January 2022

Oncode collaboration: mobilizing innate leukocytes to attack tumors

Elize Brolsma

Elize Brolsma

Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations. At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.

In 2021, Oncode Institute organized brainstorm sessions to come up with ideas for cross-disciplinary synergies between Oncode researchers to tackle difficult challenges in cancer research. A group of Oncode Investigators from different institutes* came up with an exciting new idea requiring their collaboration to become successful. This launched a new Oncode Accelerator Project.

Cancer immunotherapy is a game-changing treatment that stimulates the T-cells of our immune system to kill cancer cells. Its success revealed the major obstacle that faces cancer immunotherapy today: the resistance of tumors to this T-cell mediated therapy. The group of Oncode Investigators are joining forces to face this problem. In this Oncode Accelerator Project, they call in the help of other immune cells, so called “innate leukocytes”. These cells are present in large quantities in tumors, can be rapidly recruited from the blood stream and when steered the right way can effectively fight cancer, independent of T-cells.

The researchers want to understand which and when different types of innate leukocytes can help fight tumors. They also want to analyze how these different cells communicate which each other and with other cells, in order to discover how these cells can be manipulated to fight cancer. Finally, they want to predict the response of patients to therapies, with the ultimate aim to test them in the clinic.

Project lead Sjoerd van der Burg (Leiden University Medical Center) says: “This is the first and truly unique approach fully focused on the capitalization of the tumor-controlling role of innate leukocytes for treating tumors that are resistant to T-cell therapy. Success would revolutionize current cancer care. Within Oncode we have assembled an excellent multidisciplinary team with a high level of integrated expert knowledge. Since there are many different institutes involved, we also have access to unique toolboxes, mouse models, patient cohorts, regulatory molecule identification pipelines, facilities, drug repurposing libraries, and an antibody production platform - which will now be combined to serve this one goal in the most optimal possible way.”

*The Oncode Investigators working on this project are main applicants Sjoerd van der Burg (Leiden University Medical Center), Karin de Visser, Leila Akkari (Netherlands Cancer Institute) and Linde Meyaard (University Medical Center Utrecht). They work together with Oncode Investigators Sjaak Neefjes (Leiden University Medical Center), Tineke Lenstra, Jacco van Rheenen (Netherlands Cancer Institute), Jeroen de Ridder (University Medical Center Utrecht), Miao-Ping Chien (Erasmus MC), Sarah Derks (Amsterdam UMC, Cancer Center Amsterdam) and Carl Figdor (Radboudumc).

This project is funded by KWF Kankerbestrijding (Dutch Cancer Society) for 3.4 million euros.

Other News

Advancedworkshop1
Meeting researchers’ needs: Advanced workshop Preclinical tumor immune models for therapeutic discovery and validation
With more than a hundred participants covering a broad community interested in the OI field, this successful advanced workshop featured an exciting programme.
Vesnade Jong

<span>Vesna</span><span>de Jong</span>

Vesna is a Digital Content Manager at Lygature, and is responsible for all things digital at Oncode. Originally from Slovenia, where she finished her MA in English language and literature, life led her to the Netherlands. Vesna has more than 10 years of experience in translation and localization, and has gained extensive experience of digital communications while working for one of the biggest online travel agencies.
2 2
Highlights of the European Society of Medical Oncology Congress 2022 in Paris
Are you curious about the highlights of the European Society of Medical Oncology Congress 2022 in Paris? Oncode's Yuva Oz was there to report about all of the interesting and relevant data presented.
YuvaOz

<span>Yuva</span><span>Oz</span>

Over 17 years of experience in Molecular Biology, Yuva completed her MSc. degree at EMBL Heidelberg and conducted her PhD research on the topic of Chromatin and Biomedical Genetics at Hubrecht Institute as a Marie-Curie fellow. Interested in clinical aspects of the research, she joined to oncology specialized clinical research organization SMS-oncology, gaining experience both in clinical trial management (early phase paediatric and adult trials) and Business Development aspects. At Oncode, she is driving the industry engagement programme to enable new alliances and collaborations between Oncode and biopharma to fast-forward research and innovation. Furthermore, working closely with Oncode Investigators, she supports technology, clinical and IP assessments for efficiently translating fundamental research into clinical benefit. She is the founder and designer at Art 4 Science, a scientific visualization – graphic design company.
Un
4.UNCAN.eu is officially launching today!
Oncode is pleased to take part in the kick-off meeting of the CSA (Coordination and Support Action) for the 4.UNCAN.eu initiative, taking place today and tomorrow in Paris. Arising from the EU’s Mission on Cancer and Europe’s Beating Cancer plan, the initiative is focused on generating a research roadmap to better UNderstand poorly understood CANcers (UNCAN).
Bianca-OliviaNita

<span>Bianca-Olivia</span><span>Nita</span>